Introduction - you deserve clear answers

Facing a family history of a genetic condition can be daunting, especially when the condition is as complex as Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3 (SCA3). People often ask: Should I get tested? What will the results mean for my family and me?

Genetic testing for MJD has transformed how clinicians confirm diagnoses, guide family planning, and enrol patients in clinical trials. But it also raises deep ethical questions - about privacy, emotional impact, testing children, and even the right not to know.

I will help you understand both the benefits and ethical considerations of testing, so you can make informed decisions with confidence.

When is genetic testing helpful, and what are the challenges?

Genetic testing for MJD provides:

• Diagnostic certainty is achieved by confirming the expansion of CAG repeats in the ATXN3 gene. This ends the uncertainty that often follows years of neurological assessments¹
• Prognostic insight: the size of the repeat expansion often correlates with the age of onset and severity²
• Reproductive options: families can consider prenatal testing or preimplantation genetic diagnosis (PGD) to avoid passing on the condition³
• Access to clinical trials: Many experimental therapies require genetic confirmation of diagnosis⁴

But alongside these benefits come challenges:

• Emotional and psychological distress from knowing one’s mutation status without curative treatments⁵
• Testing of minors raises questions about consent and autonomy for an adult-onset disease⁶
• Privacy and discrimination risks, especially in employment or life insurance⁷
• Equity of access: not all regions or populations have affordable access to testing or counselling⁸

Read on – the nuances behind the decision

There is more to genetic testing than a yes/no result. Understanding when to test, how to prepare, and how to interpret results is essential. In the next sections, we’ll explore:

• The genetic background of MJD
• When testing is indicated
• Practical benefits for individuals and families
• Ethical dilemmas and safeguards
• Case scenarios that illustrate real-life decision-making

Machado-joseph disease: a quick genetic overview

MJD is the most common autosomal dominant spinocerebellar ataxia worldwide, with particularly high prevalence in Portuguese-Azorean, Japanese, and some Brazilian populations.⁹

• Cause: Expansion of CAG trinucleotide repeats in the ATXN3 gene on chromosome 14q32.1¹⁰
• Normal range: ≤44 repeats
• Pathogenic range: ≥61 repeats typically cause disease¹¹
• Intermediate alleles: 45–60 repeats may show reduced penetrance or late-onset disease¹¹
• Anticipation: larger expansions tend to appear in successive generations, causing earlier and more severe disease¹²

Clinically, MJD is characterised by progressive ataxia, dysarthria, spasticity, and oculomotor abnormalities. Symptom onset ranges from adolescence to late adulthood, depending on repeat size.^2,9

When is genetic testing indicated?

Symptomatic individuals

• People presenting with ataxia, balance problems, and a family history should undergo confirmatory genetic testing to avoid unnecessary investigations¹

Presymptomatic (predictive) testing

• Offered to at-risk adults with a family history who want to know their genetic status
• Usually, only available after age 18, to ensure informed consent^6,13

Reproductive testing

• Prenatal testing via chorionic villus sampling or amniocentesis, if one parent carries the mutation³
• Preimplantation genetic diagnosis (PGD) in IVF enables the selection of embryos without the mutation¹⁴

Testing in children

• Generally discouraged in guidelines, because MJD is adult-onset and no preventive therapy exists. Children should be allowed to decide when they are mature^6,13

Benefits in practice

Diagnostic clarity

For families who have endured years of neurological evaluations, genetic confirmation brings an end to the “diagnostic odyssey”¹

Prognosis and planning

Though not exact, the repeat length gives an estimate of age at onset. This allows families to plan financially, medically, and socially.^2,10

Family planning options

Genetic confirmation empowers informed reproductive choices:

• PGD has helped at-risk couples avoid passing the mutation on¹⁴
• Prenatal testing allows preparation, though it raises its own ethical questions¹⁵

Access to trials and research

Trials of gene silencing (antisense oligonucleotides) and ataxin-3 targeting therapies require genetic proof of diagnosis.⁴ Testing thus enables participation in cutting-edge research.

Ethical considerations and challenges

Psychological impact

• A positive result may cause depression, anxiety, or survivor's guilt in families⁵
• Some people regret predictive testing because of the emotional burden

Testing minors

• The American College of Medical Genetics and European guidelines advise against predictive testing in children for adult-onset diseases^6,13
• Respecting the child’s future autonomy is key

Right not to know

• Individuals may prefer not to undergo testing to avoid psychological harm. Clinicians must respect this choice¹⁶

Privacy and discrimination

• Genetic data raises concerns about use by employers or insurers
• Protections like the Genetic Information Nondiscrimination Act (GINA) exist in the U.S., but gaps remain globally⁷

Equity of access

• Indigenous and remote communities, such as Aboriginal populations in Northern Australia with high MJD prevalence, often face barriers to genetic counselling and testing⁸
• This raises ethical questions of justice and fairness

Family dynamics

• Testing can create conflict: one sibling may want to know, another may not
• Disclosure of results to relatives is ethically complex, balancing privacy with the duty to warn¹⁶

Guidelines, best practices, and counselling

Genetic testing for MJD should never be performed in isolation.

• Pre-test counselling: clarifies implications, limitations, and psychological risks.
• Post-test counselling: supports coping and family communication
• Multidisciplinary care: neurologists, geneticists, psychologists, ethicists¹³
• Consent protocols: ensure voluntary, informed choice
• Confidentiality safeguards: to protect genetic privacy
• Interpreting Intermediate Results: Alleles in the 45-60 repeat range create uncertainty, as they may not always cause disease, and require careful counselling¹¹

Summary

Genetic testing for Machado-Joseph disease provides clarity and options: it confirms diagnosis, supports prognosis, aids family planning, and opens doors to clinical trials.

But testing also raises profound ethical challenges:

• Psychological burden
• Testing children
• Right not to know
• Privacy and discrimination risks
• Equity of access

The key takeaway: genetic testing for MJD must be accompanied by counselling, safeguards, and respect for individual choice. It is not simply a medical procedure - it is an ethical journey for families.

FAQs – common questions on genetic testing for MJD

Q: Can everyone with a family history of MJD get tested?

A: Yes, but usually only adults (18+) after counselling, unless symptomatic. Children are not tested for predictive purposes.^6,13

Q: Does a positive result change treatment?

A: Currently, there is no cure. But it enables trial participation and helps in planning.⁴

Q: What are the risks of knowing?

A: Psychological distress, family conflict, potential discrimination in insurance or jobs.^5,7

Q: Is genetic testing available everywhere?

A: No. Access is limited in some regions, especially remote or low-resource settings.⁸

Q: Can genetic data affect my relatives?

A: Yes. If you carry the mutation, your children and siblings may be at risk. Counselling helps families manage this.¹⁶

Q: What if I don’t want to know?

A: That’s your right. The right not to know is recognised in genetic ethics.¹⁶